FARMINGDALE, N.Y., May 4, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, announced today that it will present at the MDB Capital Bright Lights Conference on Wednesday, May 11, 2011 at the Le Parker Meridien Hotel in New York City. Michael A. McManus, Jr., President and Chief Executive Officer, will address the conference at 11:30 AM Eastern time to discuss the Company’s business strategy and historical financial performance.
Bright Lights is the only conference of its kind with an exclusive focus on publicly-traded companies with market changing intellectual property (IP).
Misonix was selected from MDB’s 2011 group of “Best and Brightest” small-cap companies; a group that is advancing some of today’s most innovative and market-leading IP. Misonix is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB’s proprietary IP business intelligence platform.
To learn more about the event, please visit: http://www.mdb.com
About MDB Capital Group
MDB Capital Group, LLC is an institutional research and investment banking firm focusing exclusively on small and micro-cap companies possessing market changing, disruptive intellectual property. For more information on MDB Capital Group, visit: http://www.mdb.com
About PatentVest
PatenVest® is a proprietary intellectual property (IP) business intelligence platform developed by MDB Capital Group. PatentVest quantifies the appropriate valuation of IP and enables the emergence of IP as an investible asset class. For more information on PatentVest visit: http://www.patentvest.com
About Misonix:
Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Investor Relations Contact:
Kevin McGrath, Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com
SOURCE Misonix, Inc.
